



New Advance in Antiviral Drug Design

Collection Editor:

Dr. Santiago Garcia-Vallve

Department of Biochemistry and
Biotechnology, Universitat Rovira
i Virgili, Tarragona, Spain

Message from the Collection Editor

In wake of the formidable challenges posed by the global SARS-CoV-2 pandemic, the requirement for innovative antiviral drug design has never been more pressing. As we stand at the crossroads of scientific advancement, the need to fortify our arsenal against not only the current coronavirus, COVID-19, but also potential future viral infections has become abundantly clear. This Special Issue, titled "New Advances in Antiviral Drug Design," serves as an example of the latest advancements in the field. It aspires to amalgamate an array of research articles and reviews that shed light on compounds and extracts exhibiting remarkable inhibitory potential against coronaviruses and other viruses alike. This Special Issue also embraces the development of cutting-edge computational techniques that will revolutionize efficacy prediction for novel antiviral compounds.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)